S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
S&P 500   3,204.54 (-0.68%)
DOW   26,685.39 (-0.69%)
QQQ   257.83 (-1.18%)
AAPL   384.55 (-1.62%)
MSFT   203.94 (-1.97%)
FB   238.68 (-0.67%)
GOOGL   1,503.63 (-0.87%)
AMZN   2,987.00 (-0.73%)
NVDA   403.06 (-1.47%)
CGC   17.96 (-1.05%)
BABA   243.12 (-2.44%)
MU   49.96 (-1.09%)
GE   7.10 (-0.56%)
TSLA   1,507.82 (-2.47%)
AMD   54.50 (-1.52%)
T   30.31 (+1.00%)
ACB   12.22 (-5.05%)
F   6.80 (+0.89%)
GILD   76.12 (-0.69%)
DIS   119.36 (-1.27%)
NFLX   521.61 (-0.32%)
BAC   24.01 (-2.40%)
BA   180.84 (-3.78%)
Log in

OTCMKTS:CPHRFCipher Pharmaceuticals Stock Price, Forecast & News

$0.97
+0.01 (+1.05 %)
(As of 07/16/2020 01:09 PM ET)
Add
Compare
Today's Range
$0.96
Now: $0.97
$0.97
50-Day Range
$0.87
MA: $0.89
$0.96
52-Week Range
$0.30
Now: $0.97
$1.22
Volume4,200 shs
Average Volume4,354 shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
Cipher Pharmaceuticals Inc. operates as a specialty pharmaceutical company in Canada. The company offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; CONZIP/DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain; and Absorica, an oral retinoid indicated for the treatment of severe recalcitrant nodular acne in patients. It also provides BETEFLAM PATCH, a self-adhesive medicated plaster for the treatment of inflammatory skin conditions; Actikerall, which is indicated for the treatment of palpable or moderately thick hyperkeratotic actinic keratosis; Vaniqa, a prescription cream that reduces the growth of unwanted facial hair in women; and Ozenoxacin to treat adult and paediatric patients with impetigo. In addition, the company has various commercial and pipeline hospital products administered in the acute care setting. Its pipeline products include Dermadexin and Pruridexin for the treatment of common chronic conditions; CF101 for the treatment of plaque psoriasis and rheumatoid arthritis; DTR-001 that is in pre-clinical stage of development for the removal or reduction of the appearance of tattoos; and ASF-1096, an orphan drug indication for the treatment of anorectal indications. Cipher Pharmaceuticals Inc. has a licensing agreement with Synergy Pharmaceuticals Inc. for developing, marketing, distributing, and selling TRULANCE (plecanatide). The company was founded in 2004 and is headquartered in Mississauga, Canada.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.5Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.15 out of 5 stars


Industry, Sector and Symbol

Industry Drug Manufacturers - Specialty & Generic
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:CPHRF
Previous SymbolNASDAQ:CPHR
CUSIPN/A
CIKN/A
Phone+1-905-6025840

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Next Earnings DateN/A
OptionableNot Optionable

Receive CPHRF News and Ratings via Email

Sign-up to receive the latest news and ratings for CPHRF and its competitors with MarketBeat's FREE daily newsletter.

Cipher Pharmaceuticals (OTCMKTS:CPHRF) Frequently Asked Questions

How has Cipher Pharmaceuticals' stock been impacted by COVID-19 (Coronavirus)?

Cipher Pharmaceuticals' stock was trading at $0.6097 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CPHRF shares have increased by 58.3% and is now trading at $0.9650. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Cipher Pharmaceuticals?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cipher Pharmaceuticals in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Cipher Pharmaceuticals.

How were Cipher Pharmaceuticals' earnings last quarter?

Cipher Pharmaceuticals Inc (OTCMKTS:CPHRF) announced its earnings results on Thursday, May, 5th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.04) by $0.06. The business earned $9.10 million during the quarter, compared to analysts' expectations of $10.87 million. View Cipher Pharmaceuticals' earnings history.

What price target have analysts set for CPHRF?

2 brokers have issued 12 month price objectives for Cipher Pharmaceuticals' shares. Their forecasts range from $4.00 to $4.00. On average, they anticipate Cipher Pharmaceuticals' share price to reach $4.00 in the next year. This suggests a possible upside of 314.5% from the stock's current price. View analysts' price targets for Cipher Pharmaceuticals.

Has Cipher Pharmaceuticals been receiving favorable news coverage?

News headlines about CPHRF stock have been trending positive recently, InfoTrie Sentiment Analysis reports. The research group scores the sentiment of news coverage by monitoring more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cipher Pharmaceuticals earned a coverage optimism score of 2.1 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the near term. View the latest news about Cipher Pharmaceuticals.

Who are some of Cipher Pharmaceuticals' key competitors?

Who are Cipher Pharmaceuticals' key executives?

Cipher Pharmaceuticals' management team includes the following people:
  • Mr. Robert D. Tessarolo, Pres, CEO & Director (Age 51)
  • Mr. Stephen L. Lemieux, CFO & Sec.
  • Mr. Chris Watters, VP of Corp. Devel.
  • Dr. Diane Gajewczyk, VP of Scientific & Medical Affairs
  • Mr. Norman Evans, Consultant (Age 64)

What is Cipher Pharmaceuticals' stock symbol?

Cipher Pharmaceuticals trades on the OTCMKTS under the ticker symbol "CPHRF."

How do I buy shares of Cipher Pharmaceuticals?

Shares of CPHRF can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Cipher Pharmaceuticals' stock price today?

One share of CPHRF stock can currently be purchased for approximately $0.97.

What is Cipher Pharmaceuticals' official website?

The official website for Cipher Pharmaceuticals is www.cipherpharma.com.

How can I contact Cipher Pharmaceuticals?

Cipher Pharmaceuticals' mailing address is 2345 Argentia Rd Suite 100A, MISSISSAUGA, ON L5N 8K4, Canada. The company can be reached via phone at +1-905-6025840.

This page was last updated on 7/16/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.